Rhythm Pharmaceuticals, Inc. (RYTM): Shareholders' Equity
$139.07M
As of 2025-12-31
$102.98M
As of 2026-06-30
-19.3%
3-year compound annual growth
-3.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $139.07M | +540.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $21.73M | -87.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $169.76M | -35.8% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $264.26M | -7.0% | 2025-02-28, Balance as of period end |
| 2021-12-31 | $284.15M | +70.6% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $166.53M | -40.7% | 2023-03-01, Balance as of period end |
| 2019-12-31 | $281.02M | +14.1% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $246.26M | +70.1% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $144.79M | n/m | 2020-03-02, Balance as of period end |
| 2016-12-31 | -$32.70M | n/m | 2019-03-08, Balance as of period end |
| 2015-12-31 | -$8.00M | n/a | 2018-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗